Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of β-lactams administered by continuous infusion: a prospective observational study
Introduction
In critically ill patients, early initiation of appropriate antimicrobial therapy in sepsis and septic shock is one of the major determinants of outcome [1]. According to current practice, β-lactams are the most commonly prescribed antimicrobial agents in intensive care settings [2]. β-Lactam antibiotics exhibit time-dependent bacterial killing, such that optimal response in severe infections is achieved when the free drug concentration remains above the minimum inhibitory concentration (MIC) of the targeted organism(s) (fT>MIC) for a defined portion of the dosing interval [3]. Given the concentration-dependent selection pressure, a pharmacokinetic/pharmacodynamic (PK/PD) target greater than four times the MIC throughout the entire dosing period (100%fT>4×MIC) has been suggested to achieve microbiological eradication and to prevent the growth of resistant subpopulations [4], [5], [6]. However, these results were not confirmed in larger prospective studies and the optimal PK/PD exposure remains to be determined [7].
Moreover, optimising antimicrobial therapy still represents a complex challenge given the wide and unpredictable variability of antibiotic concentrations in critically ill patients [7], [8], [9]. A ‘one dose fits all’ approach could be especially problematic in patients with augmented renal clearance (ARC), potentially leading to subtherapeutic drug exposure and higher rates of clinical failure [10], [11], [12], [13]. In this context, recent data suggested that standard intermittent dosing is unlikely to achieve optimal antibiotic exposure in most patients with ARC [14]. Although several studies suggested a significant improvement in PK/PD target attainment and clinical success rates with high doses of β-lactams administered continuously or by prolonged infusion, evidence regarding relevant clinical outcomes in critical care patients with ARC is still limited [15], [16].
The main objective of this study was to determine whether ARC impacts negatively on PK/PD target attainment in patients treated by high doses of β-lactams administered continuously for a first infection in a surgical intensive care unit (ICU). The secondary objective was to test the association between ARC, subexposure to β-lactams and clinical outcome.
Section snippets
Study design
This prospective, single-centre, observational study was conducted in a 25-bed Surgical and Trauma ICU of CHU Pellegrin, a university hospital in Bordeaux (France), over a 9-month period (December 2016 to August 2017). Antimicrobial agent assays were performed by the university-affiliated pharmacological laboratory. Ethical approval was obtained from the Institutional Review Board (Comité de Protection des Personnes Sud-Ouest et Outre Mer III, Bordeaux, France), which waived the need for
Study population
Over the study period, 79 patients were included in the analysis. The rate of therapeutic failure was 16% (13/79). Nine patients died over the study period, two of them before end of study. No death was related to an infectious disease. The study flowchart is given Fig. 1. The main characteristics of the population, infections and outcome data are presented Table 1.
Association between creatinine clearance and β-lactam underdosing
Over the study period, 235 samples were analysed (2 samples of piperacillin were not analysed because of excessive delivery time or
Discussion
This study aimed to assess the correlation between CLCr values, subexposure to β-lactams and clinical outcome in critically ill patients receiving high doses of β-lactams administered continuously. Despite a large pharmacokinetic variability, the results suggested that (i) mean CLCr values of ≥170 mL/min were associated with higher rates of underdosing<4×MIC and (ii) subexposure<4×MIC was associated with higher rates of therapeutic failure.
This is a major concern as therapeutic failure has been
Conclusion
This study suggests that patients with CLCr ≥ 170 mL/min remain at risk of subexposure for β-lactams despite high doses of β-lactams administered continuously. Subexposure to β-lactams was associated with higher rates of therapeutic failure in patients treated for a first microbiologically documented infection in a surgical ICU. This study emphasises the need for TDM in patients with ARC, especially when targeting less-susceptible pathogens or surgical infections with limited penetration of
References (34)
- et al.
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
Int J Antimicrob Agents
(2008) - et al.
Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations
Chest
(2012) - et al.
Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study
Int J Antimicrob Agents
(2015) - et al.
Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy
J Crit Care
(2013) - et al.
Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial
Int J Antimicrob Agents
(2017) - et al.
Guidelines for management of intra-abdominal infections
Anaesth Crit Care Pain Med
(2015) - et al.
Medical treatment of prosthetic vascular graft infections: review of the literature and proposals of a Working Group
Int J Antimicrob Agents
(2015) - et al.
Augmented renal clearance in critically ill patients: etiology, definition and implications for β-lactam dose optimization
Curr Opin Pharmacol
(2015) - et al.
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum β-lactamase-producing organisms
Int J Antimicrob Agents
(2005) - et al.
Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept
Int J Antimicrob Agents
(2010)